2025 年8 月29 日，公司发布2025 半年报。根据公司2025 年半年报，公司实现营业收入43.6 亿元，同比下降 0.8%；归母净利润13.6 亿元，同比增长24.6%；扣非归母净利润11.4 亿元，同比增长2.1%；EPS 0.57元，同比增长26.7%，业绩符合预期。核心要点：创新升级，布局全球首创靶点及独家产品SSGJ-707 卡位下一代免疫疗法优质赛道，成功与辉瑞签订大额海外授权...
Source Link2025 年8 月29 日，公司发布2025 半年报。根据公司2025 年半年报，公司实现营业收入43.6 亿元，同比下降 0.8%；归母净利润13.6 亿元，同比增长24.6%；扣非归母净利润11.4 亿元，同比增长2.1%；EPS 0.57元，同比增长26.7%，业绩符合预期。核心要点：创新升级，布局全球首创靶点及独家产品SSGJ-707 卡位下一代免疫疗法优质赛道，成功与辉瑞签订大额海外授权...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.